Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B.
Su Y, et al.
JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
JCI Insight. 2018.
PMID: 30185663
Free PMC article.